
WARNING

Cladribine injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This bone marrow function should be anticipated. This is usually reversible and appears to be dose depen-dent. Serious neurological toxicity (including irre-versible paraparesis and quadraparesis) has been reported in patients who received cladribine injec-tion by continuous infusion at high doses (four to inne times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demon-strate a dose relationship; however, severe neuro-logical toxicity has been reported rarely following treatment with standard cladribine dosing regimens. Acute nephrotoxicity has been observed with high doses of cladribine injection (four to nine times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.

DESCRIPTION:

Cladribine Injection, USP (also commonly known as 2-chloro-2'-deoxy-ß-D-adenosine) is a synthetic antineo-plastic agent for continuous intravenous infusion. It is a plastic agent for continuous intravenous infusion. It is a clear, colorless, sterile, preservative-free, isotonic solution. Cladribine injection, USP is available in single-dose vials containing 10 mg (1 mg/mL) of cladribine, a chlorinated purine nucleoside analog. Each milliliter of cladribine injection, USP contains 1 mg of the active ingredient and 9 mg (0.15 mEq) of sodium chloride as an inactive ingredient. The solution has a pH range of 5.5 to 8.0. Phosphoric acid and/or dibasic sodium phosphate may have been added to adjust the pH to 6.3 ± 0.3 . The chemical name for cladribine is 2-chloro-6-amino-9-(2-deoxy-ß-D-erythropento-furanosyl) purine and the structure is represented below:



CLINICAL PHARMACOLOGY

Cellular Resistance and Sensitivity The selective toxicity of 2-chloro-2'-deoxy-B-D-adenosine towards certain normal and malignant lymphocyte and monocyte populations is based on the relative activities of deoxycytidine kinase to deoxynucleotidase. Cladribine passively crosses the cell membrane. In cells with a high ratio of deoxycytidine kinase to deoxynucleotidase, it is phosphorylated by deoxycytidine kinase to 2-chloro-2-deoxy-8-D-adenosine monophosphate (2-CdAMP). Since 2-chloro-2'-deoxy-8-D-adenosine is resistant to deami-nation by adenosine deaminase and there is little deoxy-

2-chioro-2-deoxy-B-D-adenosine is resistant to deami-nation by adenosine deaminase and there is liftle deoxy-nucleotide deaminase in lymphocytes and monocytes, 2-CdAMP accumulates intracellularly and is subse-quently converted into the active triphosphate deoxynu-cleotide, 2-chloro-2'-deoxy-B-D-adenosine triphosphate (2-CdATP). It is postulated that cells with high deoxycyti-dine kinase and low deoxynucleotidase activities will be selectively killed by 2-chloro-2' deoxy-B-D-adenosine as toxic deoxynucleotides accumulate intracellularly. Cells containing high concentrations of deoxynucleo-tides are unable to properly repair single-strand DNA breaks. The broken ends of DNA activate the enzyme poly (ADP-ribose) polymerase resulting in NAD and ATP depletion and disruption of cellular metabolism. There is evidence, also, that 2-CdATP is incorporated into the DNA of dividing cells, resulting in impairment of DNA synthesis. Thus, 2-chloro-2' deoxy-B-D-adenosine can be distinguished from other chemotherapeutic agents affecting purine metabolism in that it is cytotoxic to both actively dividing and quiescent lymphocytes and monocytes, inhibiting both DNA synthesis and repair. Pharmacokinetics

Pharmacokinetics

Rx only

Pharmacokinetics In a clinical investigation, 17 patients with Hairy Cell Leukernia (HCL) and normal renal function were treated for seven days with the recommended treatment regi-men of cladribine injection (0.09 mg/kg/day) by continu-ous intravenous infusion. The mean steady-state serum concentration was estimated to be 5.7 ng/mL with an estimated systemic clearance of 663.5 mL/h/kg when cladribine injection was given by continuous infusion over seven days. In Hairy Cell Leukemia patients, there does not appear to be a relationship between serum concentrations and ultimate clinical outcome.

toosentrations and ultimate clinical outcome. In another study, eight patients with hematologic malignancies received atwo (2) hour infusion of cladribine injection (0.12 mg/kg). The mean end-of-infusion plasma cladribine injection concentration was 48 ± 19 ng/mL. For five of these patients, the disappearance of cladribine injection could be described by either a biphasic or triphasic decline. For these patients with normal renal function, the mean terminal half-life was 5.4 hours. Mean values for clearance and steady-state volume of distribution were 978 ± 422 mL/h/kg and 4.5 ± 2.8 L/kg, respectively. Cladribine plasma concentration after intravenous administration declines multi-exponentially with an average half-life of 6.7 +/- 2.5 hours. In general, the apparent volume of distribution of cladribine is approximately 9 L/kg, indicating an extensive distribution with summately 8.1 kg, summative 9.1 kg, summative 9.1 kg, summative 9.1 kg, summative 9.1 kg, indicating an extensive distribution of cladribine is approximately 9 L/kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indicating an extensive distribution of the summative 9.1 kg, indica

mately 9 L/kg, indicating an extensive distribution in body tissues.

Cladribine penetrates into cerebrospinal fluid. One eport indicates that concentrations are approximately 5% of those in plasma. Cladribine injection is bound approximately 20% to

plasma proteins.

plasma proteins. Except for some understanding of the mechanism of cellular toxicity, no other information is available on the metabolism of cladribine injection in humans. An average of 18% of the administered dose has been reported to be excreted in urine of patients with solid tumors during a five-day continuous intravenous infusion of 3.5 to 8.1 mg/m²/day of cladribine injection. The effect of renal and hepatic impairment on the elimination of cladribine has not been investigated in humans. humans

elimination of cladribine has not been investigated in humans. **CLINICAL STUDIES:** Two single-center open label studies of cladribine injection have been conducted in patients with Hairy Cell Leukemia with evidence of active disease requiring therapy. In the study conducted at the Scripps Clinic and Research Foundation (Study A), 89 patients were treated with a single course of cladribine injection given by continuous intravenous infusion for seven days at a dose of 0.09 mg/kg/day. In the study conducted at the M.D. Anderson Cancer Center (Study B), 35 patients were treated with a seven-day continuous intravenous of a comparable dose of 0.09 mg/kg/day. In the study conducted at the M.D. Anderson Cancer Center (Study B), 35 patients were treated with a seven-day continuous intravenous infusion of cladribine injection at a comparable dose of 3.6 mg/m²/day. A complete response (CR) required clearing of the peripheral blood and bone marrow of hairy cells and recovery of the hemoglobin to 12 g/dL, platelet count to 100 x 10%/L and absolute neutrophil count to 1500 x 10%/L. A good partial response (GPR) required the same hematologic parameters as a complete response, and that fewer than 5% hairy cells remain in the bone marrow. A partial response (PR) required that hairy cells in the bone marrow be decreased by at least 50% from baseline and the same response. A pathologic parameters as for complete response. A pathologic relapse was defined as an increase in bone marrow hairy cells to 25% of pretreatment levels. A clinical relapse was defined as the recurrence of cytopenias, specifically, decreases in bene marrow hairy cells to 25% of pretreatment levels who met the criteria for a complete response but subsequently were found to have evidence of bone marrow hairy cells (< 25% of pretreatment levels) who met the criteria for a complete response but subsequently were found to have evidence of bone marrow hairy cells (< 25% of pretreatment levels) who met the criteria for a complete response but subsequently were fo responses with relapse

responses with relapse. Among patients evaluable for efficacy (N=106), using the hematologic and bone marrow response criteria described above, the complete response rates in patients treated with cladribine injection were 65% and 68% for Study A and Study B, respectively, yield-ing a combined complete response rate of 66%. Overall response rates (i.e., Complete plus Good Partial plus Partial Responses) were 89% and 86% in Study A and Study B, respectively, for a combined overall response rate of 88% in evaluable patients treated with cladribine injection. injection.

injection. Using an intent-to-treat analysis (N=123) and further requiring no evidence of splenomegaly as a criterion for CR (i.e., no palpable spleen on physical examination and \leq 13 cm on CT scan), the complete response rates for Study A and Study B were 54% and 53%, respectively, giving a combined CR rate of 54%. The overall response rates (CR + GPR + PR) were 90% and 85%, for Studies A and B, respectively, yielding a combined overall response rate of 89%.

RESPONSE RATES TO CLADRIBINE INJECTION TREATMENT IN PATIENTS WITH HAIRY CELL LEUKEMIA

	CR	Overall
Evaluable Patients N=106	66%	88%
Intent-to-treat Population N=123	54%	89%

In these studies, 60% of the patients had not received prior chemotherapy for Hairy Cell Leukemia or had undergone splenectomy as the only prior treatment and were receiving cladribine injection as a first-line treatment. The remaining 40% of the patients received cladribine injection as a second-line treatment, having been treated previously with other agents, includ-ing α-interferon and/or deoxycoformycin. The overall response rate for patients without prior chemotherapy was 92%, compared with 84% for previously treated patients. Cladribine injection is active in previously treated patients; however, retrospective analysis sug-gests that the overall response rate is decreased in patients previously treated with splenectomy or deoxy-coformycin and in patients refractory to α-interferon.

OVERALL RESPONSE RATES (CR + GPR + PR) TO CLADRIBINE INJECTION TREATMENT IN PATIENTS WITH HAIRY CELL LEUKEMIA

	OVERALL RESPONSE (N=123)	NR + RELAPSE
No Prior Chemotherapy	68/74 92%	6 + 4 14%
Any Prior Chemotherapy	41/49 84%	8 +3 22%
Previous Splenectomy	32/41* 78%	9 + 1 24%
Previous Interferon	40/48 83%	8 + 3 23%
Interferon Refractory	6/11* 55%	5 + 2 64%
Previous Deoxycoformycin	3/6* 50%	3 + 1 66%

NR = No Response * P < 0.05



45989D/Revised: August 2014



For Intravenous Infusion Only

After a reversible decline, normalization of peripheral After a reversible decline, normalization of peripheral blood counts (Hemoglobin >12 g/dL, Platelets >100 x 10⁹/L, Absolute Neutrophil Count (ANC) >1500 x 10⁶/L) was achieved by 92% of evaluable patients. The median time to normalization of peripheral counts was nine weeks from the start of treatment (Range: 2 to 72). The median time to normalization of ANC was two weeks, the median time to normalization of ANC was two weeks, the median time to normalization of Handel Count Was two weeks, the median time to normalization of ANC was two weeks, the median time to normalization of ANC was five weeks and the median time to normalization of Hemo-globin was eight weeks. With normalization of Platelet Count and Hemoglobin, requirements for platelet and RBC transfusions were abolished after Months 1 and 2, respectively, in those patients with complete response. Platelet recovery may be delayed in a minority of patients with severe baseline thrombocytopenia. Correspond-ing to normalization of ANC, a trend toward a reduced incidence of infection was seen after the third month, when compared to the months immediately preceding cladribine injection therapy (see also WARNINGS, PRECAUTIONS and ADVERSE REACTIONS).

CLADRIBINE INJECTION TREATMENT IN PATIENTS WITH HAIRY CELL LEUKEMIA TIME TO NORMALIZATION OF PERIPHERAL BLOOD COUNTS

Parameter	Median Time to Normalization of Count*
Platelet Count	2 weeks
Absolute Neutrophil Count	5 weeks
Hemoglobin	8 weeks
ANC, Hemoglobin and Platelet Count	9 weeks

*Day 1 = First day of infusion

For patients achieving a complete response, the median time to response (i.e., absence of hairy cells in bone marrow and peripheral blood together with normal-ization of peripheral blood parameters), measured from bothe marrow aling beripheral blood parameters), measured from treatment start, was approximately four months. Since bone marrow aspiration and biopsy were frequently not performed at the time of peripheral blood normalization, the median time to complete response may actually be shorter than that which was recorded. At the time of data cut-off, the median duration of complete response was greater than eight months and ranged to 254-months. Among 93 responding patients, seven had shown evidence of disease progression at the time of the data cut-off. In four of these patients, disease was limited to the bone marrow without peripheral blood abnormalities (pathologic progression), while in three patients there were also peripheral blood abnormali-ties (clinical progression). Seven patients who did not a second course of therapy. In the five patients who hod adequate follow-up, additional courses did not appear to improve their overall response.

INDICATIONS AND USAGE:

Cladribine Injection, USP is indicated for the treatment of active Hairy Cell Leukemia as defined by clinically significant anémia, neutropenia, thrombocytopenia or disease-related symptoms

CONTRAINDICATIONS:

Cladribine Injection is contraindicated in those patients who are hypersensitive to this drug or any of its components.

WARNINGS:

Due to increased risk of infection in the setting of immunosuppression with chemotherapy including cladribine, it is recommended not to administer live attenuated vac-cines to patients receiving cladribine injection.

cines to patients receiving cladribine injection. Severe bone marrow suppression, including neutro-penia, anemia and thrombocytopenia, has been com-monly observed in patients treated with cladribine injection, especially at high doses. At initiation of treatment, most patients in the clinical studies had hematologic impair-ment as a manifestation of active Hairy Cell Leukemia. Following treatment with cladribine injection, further hematologic impairment occurred before recovery of peripheral blood counts began. During the first two weeks after treatment initiation, mean Platelet Count, ANC, and Hemoglobin concentration declined and subse-quently increased with normalization of mean counts by

periprieral bodo courtis began. During the first two weeks after treatment initiation, mean Platelet Count, ANC, and Hemoglobin concentration declined and subsequently increased with normalization of mean counts by Day 12, Week 5 and Week 8, respectively. The myelo-suppressive effects of cladribine injection were most notable during the first month following treatment. Forty-four percent (44%) of patients received transfusions with Platelets during the first worthed transfusions with platelets during the first month following treatment. Forty-four percent (44%) of patients received transfusions with Platelets during the first four to eight weeks after treatment with cladhibine injection, is recommended (see **PRECAUTIONS**). Fever (T ≥ 100°F) was associated with the use of cladribine injection in approximately two-thirds of patients (131/196) in the first month of therapy. Virtually all of these patients were treated empirically with parenteral antibiotics. Overall, 47% (93/196) of all patients had fever in the setting of neutropenia (i.e., ANC ≤ 500). In a Phase I investigational study using cladribine injection in high doses (four to nine times the recommended dose for Hairy Cell Leukemia) as part of a bone marrow transplant conditioning regimen, which also included high dose cyclophosphamide and total body irradiation, acute nephrotoxicity and delayed onset neurotoxicity were observed. Thirty-one (31) poor-risk patients with drug-resistant acute leukemia (wo cases) received cladribine for 7 to 14 days prior to bone marrow transplantation. During infusion, eight patients experienced gastrointestinal symptoms. While the bone marrow was initially cleared of all hematopoietic elements, including tumor cells, leukemia eventually recurred in all treated patients. Within 7 to 13 days after starting treatment with cladribine, six patients (19%) developed manifestations of renal dysfunction (e.g., acidosis, anuria, elevated serum creatinine, etc.) and five required dialysis. Several of these patients were also being

nephrotoxic potential. Renal dysfunction was reversible in two of these patients. In the four patients whose renal function had not recovered at the time of death, autopsies were performed; in two of these, evidence of tubular damage was noted. Eleven (11) patients (35%) experi-enced delayed onset neurologic toxicity. In the majority, this was characterized by progressive irreversible motor weakness (paraparesis/quadriparesis), of the upper and/or lower extremities, first noted 35 to 84 days after starting high dose therapy with cladribine. Non-invasive testing (electromyography and nerve conduction stud-ies) was consistent with demyelinating disease. Severe neurologic toxicity has also been noted with high doses of another drug in this class. Axonal peripheral polyneuropathy was observed in a dose escalation study at the highest dose levels (approximately four times the recommended dose for Hairy Cell Leukemia) in patients not receiving cyclophos-phamide or total body irradiation. Severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. In patients with Hairy Cell Leukemia treated with the recommended treatment regimen (0.09 mg/kg/day for usphrologic toxicities. Serious (e.g. respiratory infection, pneumonia and viral skin infections), including fatal infections (e.g. sepsis) were reported (see **ADVERSE REACTIONS**). Of the 196 Hairy Cell Leukemia patients entered in the two trias, there were eight deaths following treatment. Of these, six were of infectious etiology, including three pneumonias, and two occurred in the first month follow-ing cladribine therapy. Of the eight deaths, six occurred in previously treated patients who were refractory to cinterfero.

a-interferon. Benzyl alcohol is a constituent of the recommended diluent for the seven-day infusion solution. Benzyl alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants (see **DOS**-"Gasping Syndrome" in premat AGE AND ADMINISTRATION).

AGE AND ADMINISTRATION). Pregnancy Category D Cladribine can cause fetal harm when administered to a pregnant woman. Although there is no evidence of teratogenicity in humans due to cladribine, other drugs which inhibit DNA synthesis have been reported to be teratogenic in humans. Cladribine is teratogenic in ani-mals. Advise females of reproductive potential to use highly effective contraception during treatment with cladribine. If cladribine is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Cladribine is teratogenic in mice and rabbits and consequently has the potential to cause fetal harm when administered to a pregnant woman. A signifi-cant increase in fetal variations was observed in mice receiving 1.5 mg/kg/day (4.5 mg/m²) and increased resorptions, reduced litter size and increased fetal malformations were observed when mice received

resorptions, reduced litter size and increased fetal malformations were observed when mice received 3 mg/kg/day (9 mg/m²). Fetal death and malformations were observed in rabbits that received 3 mg/kg/day (33 mg/m²). No fetal effects were seen in mice at 0.5 mg/kg/day (1.5 mg/m²) or in rabbits at 1 mg/kg/day (11 mg/m²).

PRECAUTIONS:

General

General Cladribine injection is a potent antineoplastic agent with potentially significant toxic side effects. It should be administered only under the supervision of a physician experienced with the use of cancer chemotherapeutic agents. Patients undergoing therapy should be closely observed for signs of hematologic and non-hematologic toxicity. Periodic assessment of peripheral blood counts, particularly during the first four to eight weeks post-treatment, is recommended to detect the development of anemia, neutropenia and thrombocytopenia and for early detection of any potential sequelae (e.g., infection or bleeding). As with other potent chemotherapeutic agents, monitoring of renal and hepatic function is also recommended, especially in patients with underly-ing kidney or liver dysfunction (see WARNINGS and ADVERSE REACTIONS). Fever was a frequently observed side effect during

ADVERSE REACTIONS). Fever was a frequently observed side effect during the first month on study. Since the majority of fevers occurred in neutropenic patients, patients should be closely monitored during the first month of treatment and empiric antibiotics should be initiated as clinically indicated. Although 69% of patients developed fevers, less than 1/3 of febrile events were associated with documented infection. Given the known myelosuppres-sive effects of cladribine, practitioners should carefully to patients with active infections (see WARNINGS and ADVERSE REACTIONS).

to patients with active infections (see WARNINGS and ADVERSE REACTIONS). There are inadequate data on dosing of patients with renal or hepatic insufficiency. Development of acute renal insufficiency in some patients receiving high doses of cladribine has been described. Until more information is available, caution is advised when admin-istering the drug to patients with known or suspected renal or hepatic insufficiency (see WARNINGS). Rare cases of tumor lysis syndrome have been reported in patients treated with cladribine with other hematologic malignancies having a high tumor burden. Cladribine injection must be diluted in designated intravenous solutions prior to administration (see DOS-AGE AND ADMINISTRATION).

AGE AND ADMINISTRATION). Laboratory Tests During and following treatment, the patient's hematologic profile should be monitored regularly to determine the degree of hematopoietic suppression. In the clinical studies, following reversible declines in all cell counts, the mean Platelet Count reached 100 x 10⁹/L by Day 12, the mean Absolute Neutrophil Count reached 1500 x 10⁶/L by Week 5 and the mean Hemoglobin reached 12 g/dL by Week 8. After peripheral counts have nor-malized, bone marrow aspiration and biopsy should be performed to confirm response to treatment with cladribine. Febrile events should be investigated with

appropriate laboratory and radiologic studies. Periodic assessment of renal function and hepatic function should be performed as clinically indicated.

Drug Interactions

There are no known drug interactions with cladribine injec-tion. Caution should be exercised if cladribine injection is administred before, after, or in conjunction with other drugs known to cause immunosuppression or myelo-suppression (see **WARNINGS**).

Carcinogenesis

No animal carcinogenicity studies have been conducted with cladribine. However, its carcinogenic potential can-not be excluded based on demonstrated genotoxicity of cladribine.

Mutagenesis As expected for compounds in this class, the actions of cladribine yield DNA damage. In mammalian cells in culture, cladribine caused the accumulation of DNA strand breaks. Cladribine was also incorporated into DNA of human lymphoblastic leukemia cells. Cladribine was not mutagenic *invitro* (Ames and Chinese hamster ovary cell gene mutation tests) and did not induce unscheduled DNA synthesis in primary rat hepatocyte cul-tures. However, cladribine was clastogenic both *in vitro* (chromosome aberrations in Chinese hamster ovary cells) and *in vivo* (mouse bone marrow micronucleus test).

Impairment of Fertility The effect on human fertility is unknown. When adminis-tered intravenously to Cynomolgus monkeys, cladribine has been shown to cause suppression of rapidly generat-ing cells, including testicular cells.

Pregnancy Pregnancy Category D (see WARNINGS).

Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reac-tions in nursing infants from cladribine, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug for the mother. for the mother

Pediatric Use Safety and effectiveness in pediatric patients have not been established. In a Phase I study involving patients 1 to 21 years old with relapsed acute leukemia, cladribine injection was given by continuous intravenous infusion in doses ranging from 3 to 10.7 mg/m²/day for five days (one-half to twice the dose recommended in Hairy Cell Leukemia). In this study, the dose-limiting toxicity was severe myelosuppression with profound neutro-penia and thrombocytopenia. At the highest dose (10.7 mg/m²/day), three of seven patients developed irreversible myelosuppression and fatal systemic bacterial or fungal infections. No unique toxicities were noted in this study(1) (see WARNINGS and ADVERSE REACTIONS). REACTIONS).

Geriatric Use

Geriatric Use Clinical studies of cladribine did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified dif-ferences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients patients

ADVERSE REACTIONS:

Clinical Trials Experience Adverse drug reactions reported by ≥ 1% of cladribine-treated patients with HCL noted in the HCL clinical dataset (studies K90-091 and L91-048, n=576) are shown in the table below.

$\begin{array}{l} \mbox{Adverse Drug Reactions in} \geq 1\% \mbox{ of Patients Treated} \\ \mbox{ with Cladribine in HCL Clinical Trials} \end{array}$

System Organ Class Preferred Term	Cladribine (n=576) %
Blood and Lymphatic System Dia (see also sections WARNINGS and	
Anemia	1
Febrile neutropenia	8
Psychiatric Disorders	
Anxiety	1
Insomnia	3
Nervous System Disorders	
Dizziness	6
Headache	14
Cardiac Disorders	
Tachycardia	2
Respiratory, Thoracic and Media	astinal Disorders
Breath sounds abnormal	4
Cough	7
Dyspnea*	5
Rales	1
Gastrointestinal Disorders	
Abdominal pain**	4
Constipation	4
Diarrhea	7
Flatulence	1
Nausea	22
Vomiting	9

Adverse Drug Reactions in ≥ 1% of Patients Treated

with Cladribine in HCL Clinical Trials (cont'd)		
System Organ Class Preferred Term	Cladribine (n=576) %	
Skin and Subcutaneous Tissue Disorders		
Ecchymosis	2	
Hyperhidrosis	3	
Petechiae	2	
Pruritus	2	
Rash***	16	
Musculoskeletal, Connective Tissue, and Bone Disorders		
Arthralgia	3	
Myalgia	6	
Pain****	6	
General Disorders and Administration Site Conditions (see also sections WARNINGS and PRECAUTIONS)		
Administration site reaction*****	11	
Asthenia	6	
Chills	2	
Decreased appetite	8	
Fatigue	31	
Malaise	5	
Muscular weakness	1	
Edema peripheral	2	
Edonia polipilorai		
Pyrexia	33	

- Dyspnea includes dyspnea, dyspnea exertional, and
- wheezing Abdominal pain includes abdominal discomfort, abdominal ++

- ** Abdominal pain includes abdominal discomfort, abdomina pain, and abdominal pain (lower and upper) *** Rash includes erythema, rash, and rash (macular, macula-papular, papular, pruritic, pustular and erythematous) **** Pain includes pain, back pain, chest pain, arthrittis pain, bone pain, and pain in extremity ****** Administration site reaction includes administration site reaction, catheter site (cellulitis, erythema, hemorrhage, and pain), and infusion site reaction (erythema, edema, and pain)

The following safety data are based on 196 patients with Hairy Cell Leukemia: the original cohort of 124 patients plus an additional 72 patients enrolled at the same two centers after the original enrollment cutoff. In Month 1 of the Hairy Cell Leukemia clinical trials, severe neutropenia was noted in 70% of patients, fever in 69%, and infection was documented in 28%. Most mon-hematologic adverse experiences were mild to moderate in severity. Myelosuppression was frequently observed during

Myelosuppression was frequently observed during the first month after starting treatment. Neutropenia (ANC < 500 x10⁶/L) was noted in 70% of patients, com-pared with 26% in whom it was present initially. Severe anemia (Hemoglobin<8.5 g/dL) developed in 37% of patients, compared with 10% initially and thrombocytopenia (Platelets < 20 x 10⁹/L) developed in 12% of patients, compared to 4% in whom it was noted initially.

in 12% of patients, compared to 4% in whom it was noted initially. During the first month, 54 of 196 patients (28%) exhibited documented evidence of infection. Serious infections (e.g., septicemia, pneumonia) were reported in 6% of all patients; the remainder were mild or moder-ate. Several deaths were attributable to infection and/or complications related to the underlying disease. During the second month, the overall rate of documented infec-tion was 6%: these infections were mild to moderate and tion was 6%: these infections were mild to moderate and no severe systemic infections were seen. After the third month, the monthly incidence of infection was either less than or equal to that of the months immediately

less than or equal to that of the months immediately preceding cladribine therapy. During the first month, 11% of patients experienced severe fever (i.e., ≥ 104°F). Documented infections were noted in fewer than one-third of febrile episodes. Of the 196 patients studied, 19 were noted to have a documented infection in the month prior to treatment. In the month following treatment, there were 54 episodes of documented infection: 23 (42%) were bacterial, 11 (20%) were viral and 11 (20%) were fungal. Seven (7) of 8 documented episodes of herpes zoster occurred during the month following treatment. Fourteen (14) of 16 episodes of documented fungal infections occurred 16 episodes of documented fungal infections occurred in the first two months following treatment. Virtually all of these patients were treated empirically with antibiotics (see WARNINGS and PRECAUTIONS).

Analysis of Upphocyte subsets indicates that treat-ment with cladribine is associated with prolonged depression of the CD4 counts. Prior to treatment, the mean CD4 count was 766/µL. The mean CD4 count nadir, which occurred four to six months fallowing treat-ment, was 272/µL. Filteen (15) months after treatment, mean CD4 counts remained below 500/µL. CD8 counts were behaved similary. though increasing counts were

mean CD4 counts remained below 500/µL. CD8 counts behaved similarly, though increasing counts were observed after nine months. The clinical significance of the prolonged CD4 lymphopenia is unclear. Another event of unknown clinical significance includes the observation of prolonged bone marrow hypocellularity. Bone marrow cellularity of < 35% was noted after four months in 42 of 124 patients (34%) treated in the two pivotal trials. This hypocellularity was noted as late as Day 1010. It is not known whether the hypocellularity is the result of cladhione toxicity. There was no apparent clinical effect on the peripheral blood counts.

The vast majority of rashes were mild. Most episodes of nausea were mild, not accompanied by voniting, and did not require treatment with antiemetics. In patients requiring antiemetics, nausea was easily controlled, most frequently with chlorpromazine. When used in other clinical settings the following ADRs were reported: bacteremia, cellulitis, localized infection, pneumonia, anemia, thrombocytopenia (with bleeding or petechiae), phlebitis, purpura, crepitations, localized edema and edema.

For a description of adverse reactions associated with use of high doses in non-Hairy Cell Leukemia patients, see WARNINGS.

Postmarketing Experience

The following additional adverse reactions have been reported since the drug became commercially avail-able. These adverse reactions have been reported primarily in patients who received multiple courses of cladribine injection:

Infections and infestations: Septic shock. Opportunistic infections have occurred in the acute phase of treatment. Blood and lymphatic system disorders: Bone marrow suppression with prolonged parcytopenia, including some reports of aplastic anemia; hemolytic anemia (including autoimmune hemolytic anemia), which was reported in patients with lymphoid malignancies, occur-ring within the first few weeks following treatment. Rare cases of myelodysplastic syndrome have been reported.

Immune system disorders: Hypersensitivity.

Metabolism and nutrition disorders: Tumor lysis

Psychiatric disorders: Confusion (including disorientation).

Hepatobiliary disorders: Reversible, generally mild increases in bilirubin (uncommon) and transaminases. Nervous System disorders: Depressed level of con-

Nervous System alsorders: Depressed level of con-sciousness, neurological toxicity (including peripheral sensory neuropathy, motor neuropathy (paralysis), polyneuropathy, paraparesis); however, severe neu-rotoxicity has been reported rarely following treatment with standard cladribine dosing regimens. Eye disorders: Conjunctivitis.

Respiratory, thoracic and mediastinal disorders: Pul-monary interstitial infiltrates (including lung infiltration, interstitial lung disease, pneumonitis and pulmonary fibrosis); in most cases, an infectious etiology was identified.

Skin and tissue disorders: Urticaria, hypereosinophilia; Stevens-Johnson. In isolated cases toxic epidermal necrolysis has been reported in patients who were receiving or had recently been treated with other medi-cations (e.g., allopurinol or antibiotics) known to cause these syndromes.

Renal and urinary disorders: Renal failure (including renal failure acute, renal impairment).

OVERDOSAGE:

OVERDOSAGE: High doses of cladribine have been associated with: irreversible neurologic toxicity (paraparesis/quadri-paresis), acute nephrotoxicity, and severe bone mar-row suppression resulting in neutropenia, anemia and thrombocytopenia (see WARNINGS). There is no known specific antidote to overdosage. Treatment of overdos-age consists of discontinuation of cladribine, careful observation, and appropriate supportive measures. It is not known whether the drug can be removed from the circulation by dialysis or hemofiltration.

DOSAGE AND ADMINISTRATION:

DOSAGE AND ADMINISTRATION: Usual Dosage The recommended dose and schedule of cladribine injection for active Hairy Cell Leukemia is as a single course given by continuous infusion for seven consecu-tive days at a dose of 0.09 mg/kg/day. Deviations from this dosage regimen are not advised. If the patient does not respond to the initial course of cladribine injection for Hairy Cell Leukemia, it is unlikely that they will benefit from additional courses. Physicians should consider delaying or discontinuing the drug if neurotoxicity or renal toxicity occurs (see WARNINGS). Specific risk factors predisposing to increased toxic-ity from cladribine injection have not been defined. In view of the known toxicities of agents of this class, it would be prudent to proceed carefully in patients with known or suspected renal insufficiency or severe bone marrow impairment of any etiology. Patients should be monitored closely for hematologic and non-hematologic

monitored closely for hematologic and non-hematoxicity (see WARNINGS and PRECAUTIONS)

Preparation and Administration of Intravenous

Solutions Cladribine injection must be diluted with the designated Claonoine injection must be oliuted with the designated diluent prior to administration. Since the drug product does not contain any antimicrobial preservative or bacteriostatic agent, aseptic technique and proper environmental precautions must be observed in preparation of cladribine injection solutions.

To prepare a single daily dose Cladribine injection should be passed through a sterile 0.22µm disposable hydrophilic syringe filter prior to intro-duction into the infusion bag, prior to each daily infusion. Add the calculated dose (0.09 mg/kg or 0.09 mL/kg) of cladribine injection through the sterile filter to an infusion bag containing 500 mL of 0.9% Sodium Chloride Injec-tion, USP. Infuse continuously over 24 hours. Repeat daily for a total of seven consecutive days. The use of 5% dextrose as a diluent is not recommended because of increased degradation of cladribine. Admixtures of cladribine injection are chemically and physically stable cladribine injection are chemically and physically stable for at least 24 hours at room temperature under normal room fluorescent light in Baxter Viaffex® PVC infusion containers. Since limited compatibility data are available, adherence to the recommended diluents and infusion systems is advised.

	Dose of	Recommended	Quantity of
	Cladribine Injection	Diluent	Diluent
24-hour infusion method	1 (day) x 0.09 mg/kg	0.9% Sodium Chloride Injection, USP	500 mL

To prepare a 7-day infusion

To prepare a 7-day infusion The seven-day infusion solution should only be prepared with Bacteriostatic 0.9% Sodium Chloride Injection, USP (0.9% benzyl alcohol preserved). In order to minimize the risk of microbial contamination, both cladribine injec-tion and the diluent should be passed through a sterile 0.22µm disposable hydrophilic syringe filter as each solution is being introduced into the infusion reservoir. First add the calculated dose of cladribine injection (7 days x 0.09 mg/kg or mL/kg) to the infusion reservoir through the sterile filter. Then add a calculated amount of Bacteriostatic 0.9% Sodium Chloride Injection, USP (0.9% benzyl alcohol preserved) also through the filter to bring the total vol-ume of the solution to 100 mL. After completing solution preparation, clamp off the line, disconnect and discard the filter. Aseptically aspirate air bubbles from the reser-voir as necessary using the syringe and a dry second sterile filter or a sterile vent filter assembly. Reclamp the line and discard the syringe and filter assembly. Infuse continuously over seven days. Solutions prepared with Bacteriostatic Sodium Chloride Injection for individuals weighing more than 85 kg may have reduced preserva-tive effectiveness due to greater dilution of the benzyl alcohol preservative. Admixtures for the seven-day infusion have demonstrated acceptable chemical and physical stability for at least seven days in the SIMS Deltec MEUCATION CASSETTE™ Meservoir. physical stability for at least seven days in the SIMS Deltec MEDICATION CASSETTE™ Reservoir.

	Dose of Cladribine Injection	Recommended Diluent	Quantity of Diluent
7-day infusion method (use sterile 0.22µm filter when preparing infusion solution)	7 (days) x 0.09 mg/kg	Bacteriostatic 0.9% Sodium Chloride Injection, USP (0.9% benzyl alcohol)	q.s. to 100 mL

Since limited compatibility data are available, adherence to the recommended diluents and infusion systems is advised. Solutions containing cladribine injection should not be mixed with other intravenous drugs or additives or infused simultaneously dis a comparison intercomputing intercompatibility test via a common intravenous line, since compatibility test-ing has not been performed. Preparations containing benzyl alcohol should not be used in neonates (see WARNINGS).

Care must be taken to assure the sterility of prepared solutions. Once diluted, solutions of cladribine injec-tion should be administered promptly or stored in the refrigerator (2° to 8°C) for no more than eight hours prior to start of administration. Vials of cladribine injection are for single-use only. Any unused portion should be discarded in an appropriate manner (see **Handling** and **Discosa**). and Disposal).

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to admin-istration, whenever solution and container permit. A precipitate may occur during the exposure of cladribine injection to low temperatures; it may be resolubilized by allowing the solution to warm naturally to room temperature and by shaking vigorously. **DO NOT HEAT** OR MICROWAVE

OR MICROWAVE. Chemical Stability of Vials When stored in refrigerated conditions between 2° to 8°C (36° to 46°F) and protected from light, unopened vials of cladribine injection are stable until the expiration date indicated on the package. Freezing does not adversely affect the solution. If freezing occurs, thaw naturally to room temperature. Do NOT heat or microwave. Once thawed, the vial of cladribine injection is stable until expiry if refrigerated. DO NOT refreeze. Once diluted, solutions containing cladribine injection should be administered promptly or stored in the refrigerator (2° to 8°C) for no more than 8 hours prior to administration. Handline and Disnocal

Handling and Disposal

Handling and Disposal The potential hazards associated with cytotoxic agents are well established and proper precautions should be taken when handling, preparing, and administering cladribine injection. The use of disposable gloves and protective garments is recommended. If cladribine injection contacts the skin or mucous membranes, wash the involved surface immediately with copious amounts of water. Several guidelines on this subject have been published.^[26] There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. Refer to your Institution's guidelines and all applicable state/local regulations for disposal of cytotoxic waste. HOW SUPPLIED:

HOW SUPPLIED: Product NDC.

No. No. 104010 63323-140-10

Cladribine Injection, USP is available as 10 mg per 10 mL (1 mg per mL), 10 mL fill in a 20 mL single-dose vial, packaged individually.

Store refrigerated 2° to 8°C (36° to 46°F). Protect from

light. This container closure is not made with natural rubber latex.

- REFERENCES: 1. Santana VM, Mirro J, Harwood FC, et al: A phase I clinical trial of 2-Chloro-deoxyadenosine in pediatric patients with acute leukemia. J. Clin. Onc., 9: 416 (1991).
- (1991).
 Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington D.C. 20402.
 AMA Council Report. Guidelines for Handling Parenteral Antineoplastics, JAMA, March 15 (1985).
 National Study Commission on Cytotoxic Exposure-Recommendations for Handling Cytotoxic Agents.

Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Manacohusette 20145 Massachusetts 02115.

- Massachusetts 02/15.
 Clinical Oncological Society of Australia: Guide-lines and Recommendations for Safe Handling of Antineoplastic Agents, <u>Med. J. Australia</u> 1:425 (1983).
 Jones RB, *et al.* Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Cen-ter. <u>Ca. A Cancer Journal for Clinicians</u>, Sept/Oct. 258-263 (1983).
 American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic Drugs in Hospitals. <u>Am. J. Hosp. Pharm</u>, 42:131 (1985).
 OSHA Work-Practice Guidelines for Personnel Dealing with Cytotoxic (antineoplastic) Drugs. <u>Am. J. Hosp. Pharm</u>, 43:1193 (1986).

The brand names mentioned in this document are the trademarks of their respective owners



45989D

Revised: August 2014